Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2025 · 10-Q
Revenue$13.68M$13.68M−89.3% vs Q2 2024 Net Income-$30.34M-$30.34MN/M vs Q2 2024 EPS Diluted-$0.02-$0.02N/M vs Q2 2024 Operating Income-$30,288,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$34,855,000N/M Margins · derivedOperating margin-221.5%−275.0 pt vs Q2 2024
Net margin-221.8%−276.0 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 13, 2025 · 44 d after period end